A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
TRIlogy-3
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
3 other identifiers
interventional
168
8 countries
71
Brief Summary
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 multiple-myeloma
Started Feb 2026
Shorter than P25 for phase_2 multiple-myeloma
71 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 25, 2025
CompletedFirst Posted
Study publicly available on registry
December 5, 2025
CompletedStudy Start
First participant enrolled
February 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 14, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 12, 2028
September 25, 2026
September 1, 2026
1.3 years
November 25, 2025
September 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Response Rate (ORR)
Up to 2 years and 9 months
Secondary Outcomes (19)
Very Good Partial Response (VGPR) or Better Rate
Up to 2 years and 9 months
Complete Response (CR) or Better Rate
Up to 2 years and 9 months
Duration of Response (DoR)
Up to 2 years and 9 months
Progression-Free Survival (PFS)
Up to 2 years and 9 months
Overall Survival (OS)
Up to 2 years and 9 months
- +14 more secondary outcomes
Study Arms (1)
JNJ-79635322
EXPERIMENTALParticipants will receive JNJ-79635322 as an injection under the skin.
Interventions
Eligibility Criteria
You may qualify if:
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:
- MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
- Measurable disease at screening as assessed by central laboratory
- Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)
- Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria
- Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent
- Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2 at screening and immediately before the start of study treatment administration
You may not qualify if:
- Suspected or known allergies, hypersensitivity, or intolerance to excipients of JNJ-79635322
- Had major surgery within 2 weeks before first dose or has planned major surgery during study treatment phase
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Participant has leptomeningeal disease
- Participant has a prior or concurrent second malignancy the natural history or treatment of which could likely interfere with any study endpoints of safety or the efficacy of the study treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (71)
O Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama, 35294, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
City of Hope
Duarte, California, 91010, United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, 92618, United States
Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720, United States
University of California San Francisco
San Francisco, California, 94143, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012, United States
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
Cancer Specialists of North Florida
Jacksonville, Florida, 32256, United States
Emory University
Atlanta, Georgia, 30322, United States
Northside Hospital Cancer Institute
Atlanta, Georgia, 30342, United States
Cancer Care Specialists of Central Illinois
O'Fallon, Illinois, 62269, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Mission Cancer Blood
Waukee, Iowa, 50263, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Cleveland Clinic Foundtation
Cleveland, Ohio, 44195, United States
Oncology Associates of Oregon PC Willamette Valley Cancer Institute
Eugene, Oregon, 97401, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
Texas Oncology
Austin, Texas, 78705, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Oncology Consultants Texas
Houston, Texas, 77030, United States
Texas Oncology - Northeast
Tyler, Texas, 75702, United States
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
NorthWest Medical Specialties, PLLC
Tacoma, Washington, 98405, United States
Peking Union Medical College Hospital
Beijing, 100006, China
Beijing Chaoyang Hospital
Chaoyang District, 100020, China
Sun Yat Sen University Cancer Center
Guangzhou, 510700, China
Shanghai Fourth People s Hospital
Shanghai, 200434, China
Ha'Emek Medical Center
Afula, 1834111, Israel
Samson Assuta Ashdod University Hospital
Ashdod, 7747629, Israel
Hillel Yaffe Medical Center
Hadera, 3820302, Israel
Hadassah Medical Center
Jerusalem, 9112000, Israel
Rabin Medical Center
Petah Tikva, 4941492, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
ASST Papa Giovanni XXIII Bergamo
Bergamo, 24127, Italy
Policlinico Sant'Orsola Malpighi
Bologna, 40138, Italy
Azienda Ospedaliera S Croce e Carle Cuneo
Cuneo, 12100, Italy
Azienda Ospedaliero Universitaria Careggi
Florence, 50134, Italy
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
Palermo, 90127, Italy
IRCCS Policlinico San Matteo, Università degli studi di Pavi
Pavia, 27100, Italy
Presidio Ospedaliero Pescara
Pescara, 65124, Italy
AOU Policlinico Umberto I
Roma, 00161, Italy
Centro Ricerche Cliniche di Verona S r l
Verona, 37134, Italy
National Hospital Organization Shibukawa Medical Center
Gunma, 377-0280, Japan
National Hospital Organization Okayama Medical Center
Okayama, 701-1192, Japan
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
Brzozów, 36 200, Poland
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
Kielce, 25 734, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
Krakow, 30 688, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi
Lodz, 93 513, Poland
Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
Lublin, 20 081, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, 60-569, Poland
Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
Torun, 87 100, Poland
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
Wroclaw, 50 367, Poland
Chonnam National University Hwasun Hospital
Jeollanam-do, 58128, South Korea
Seoul National University Hospital
Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
Asan Medical Center
Seoul, 05505, South Korea
Samsung Medical Center
Seoul, 06351, South Korea
The Catholic University of Korea Seoul St Marys Hospital
Seoul, 06591, South Korea
Ankara University Medical Faculty
Ankara, 06590, Turkey (Türkiye)
Liv Hospital Ankara
Ankara, 06680, Turkey (Türkiye)
Memorial Antalya Hospital
Antalya, 07025, Turkey (Türkiye)
Medipol University Hospital
Istanbul, 34214, Turkey (Türkiye)
Istanbul Florance Nightingale Hospital
Istanbul, 34381, Turkey (Türkiye)
Sakarya Üniversitesi Tıp Fakültesi Hastanesi
Sakarya, 54050, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 25, 2025
First Posted
December 5, 2025
Study Start
February 8, 2026
Primary Completion (Estimated)
June 14, 2027
Study Completion (Estimated)
December 12, 2028
Last Updated
September 25, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will share
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu